WASHINGTON, Sept 6, 2012 /PRNewswire-USNewswire/ -- This year, the biopharmaceutical research industry will have invested $500 billion in research and development since 2000. In 2011, research and development in the biopharmaceutical sector represented 20 percent of all research and development undertaken by American businesses. This investment by a single industry is one of the reasons that the U.S. leads the world in R&D. However, in a time of uncertainty when the country is facing major policy decisions that will shape the future of health care and our economy, what must happen to sustain this investment and the work of the researchers who drive it?
John Castellani, president and CEO of the Pharmaceutical Research and Manufacturers of America (PhRMA), will discuss the need for policies that support innovation as a key component of the nation's economic and health future, the questions facing policymakers today, and the important work of biopharmaceutical researchers in a National Press Club Newsmaker press conference 10:00 a.m.., Thursday, September 20, 2012, National Press Building, 529 14th St., NW, Washington, D.C.
Castellani will mark the progress made as a result of the $500 billion investment in the 2000's and look ahead at how the industry and the broader health care ecosystem can build upon that success.